11C-Radiopharmaceutical
11C-labeled radiopharmaceuticals are widely utilized in molecular imaging and drug discovery, offering valuable insights for the early diagnosis of targeted diseases and therapeutic monitoring. Alfa Cytology specializes in the development of 11C-radiopharmaceuticals, delivering high-quality solutions to support precision medicine and advance clinical research efforts.
Overview of 11C-Radiopharmaceutical
11C-radiopharmaceuticals are a class of radioactive compounds labeled with the carbon-11 isotope, extensively used in molecular imaging, particularly positron emission tomography (PET). The short half-life of 11C, approximately 20.3 minutes, allows for rapid metabolism in the body, providing real-time biological information. This characteristic makes 11C-radiopharmaceuticals especially suitable for studying drug metabolism, receptor binding, neurotransmission, tumor labeling, and the early diagnosis of various diseases.
![Nuclear formation of carbon-11 and its transformation to commonly used 11C precursors, with the versatility of the [11C]CO building block for the labeling of diverse functional groups in PET radiochemistry.](https://www.rdcthera.com/wp-content/themes/rdc/upload/2-1-1-1-8-11c-radiopharmaceutical-1.jpg)
Fig 1. Nuclear formation of carbon-11 and its transformation to commonly used 11C precursors, with the versatility of the [11C]CO building block for the labeling of diverse functional groups in PET radiochemistry. (DAHL K, et al., 2023)
Applications of 11C-Labeled Radiopharmaceuticals
Medical Imaging and Disease Diagnosis
11C-labeled radiopharmaceuticals are extensively used in molecular imaging studies for early diagnosis of tumors, neurodegenerative conditions, cardiovascular diseases, and more. They facilitate monitoring disease progression and evaluating the effectiveness of treatments.
Neuroscience and Brain Research
11C-radiopharmaceuticals are instrumental in studying the brain's neurotransmitter systems, receptor activities, and overall brain metabolism. This helps elucidate the mechanisms behind neurological disorders and provides valuable data for developing targeted therapies.
Drug Discovery and Metabolism Research
These radiopharmaceuticals enable researchers to track real-time metabolic pathways and biodistribution of drugs within the body, aiding in the optimization of drug design and therapeutic regimens.
Infection and Immunity Research
These radiopharmaceuticals allow the study of infections, immune responses, and autoimmune diseases. They help monitor the distribution and activity of the immune system and track the progression of infectious diseases.
Our Services
Specializing in 11C-radiopharmaceuticals, Alfa Cytology offers high-quality development services to advance targeted medicine and molecular imaging research. Our comprehensive services encompass the entire process, from drug labeling and manufacturing to preclinical evaluation, thereby facilitating progress in early disease diagnosis and personalized treatment strategies.
Workflow of 11C-Radiopharmaceutical Development
Target Identification
Thoroughly define research objectives by identifying precise molecular targets, evaluating potential drug candidates, and assessing specific preclinical or research needs. This foundational step helps to clarify the direction and strategic goals of the development process.
Synthesis and Labeling
In the chemistry lab, conduct sophisticated chemical labeling processes by integrating selected molecules with 11C isotopes. This step involves meticulous synthesis techniques to ensure both the stability and efficacy of the labeled compounds, laying the groundwork for reliable imaging studies.
Quality Control
Implement comprehensive quality control measures, including rigorous assessments of purity, specific radioactivity, and overall integrity of the labeled compound. These steps are crucial to ensuring the pharmacological safety, consistency, and reliability required for subsequent research phases.
Preclinical Support and Data Analysis
Provide extensive preclinical support, incorporating advanced imaging applications and pharmacokinetic studies, to thoroughly evaluate the drug's in vivo performance. This includes analyzing biodistribution, target engagement, and metabolic pathways, ultimately assessing its potential efficacy and suitability for preclinical applications.
Equipped with state-of-the-art laboratory technology and extensive research and development expertise, Alfa Cytology is adept at overcoming the challenges associated with 11C radiopharmaceutical development. If you are interested in our services or need further information, please don't hesitate to contact us.
Reference
- DAHL K, LINDBERG A, VASDEV N, et al. Reactive Palladium-Ligand Complexes for (11)C-Carbonylation at Ambient Pressure: A Breakthrough in Carbon-11 Chemistry [J]. Pharmaceuticals (Basel, Switzerland), 2023, 16(7).
For research use only. Not intended for any clinical use.
Related Service
